Objetivo: Verificar o uso da polimedicação em usuários de varfarina e sua associação com variáveis clínicas. Métodos: estudo transversal, com usuários de varfarina, de ambos os sexos. Para a coleta dos dados foi utilizado questionário estruturado, com perguntas abertas e fechadas, sobre dados socioeconômicos, clínicos e aspectos relacionados à farmacoterapia (reações adversas, interações medicamentosas, índices de pressão arterial sistêmica, valores de glicemia de jejum, prática de automedicação, sobrepeso, episódios de sangramento e de tromboembolismo). Resultados: a média de idade dos participantes foi de 69,1 ± 13,6 anos, maioria do sexo feminino (64,6%), casado (43,8%), e de etnia branca (85,4%). Quanto a escolaridade, 41,7% cursaram ensino fundamental incompleto. Os pacientes polimedicados totalizaram 89,6%, e os pacientes em uso de dez ou mais medicamentos, 31,3%. A média de medicamentos foi 8,2 ± 3,5 fármacos/paciente. Ocorreu associação entre polimedicação, ocorrência de reações adversas (94,7% vs 5,3%; p = 0,042) e o número de potenciais interações medicamentosas, totais (8,9 ± 5,0 vs 1,2 ± 1,6; p = 0,001) e graves (3,1 ± 2,4 vs 0,4 ± 0,6; p = 0,017). As demais variáveis estudadas não foram associadas com a polimedicação. Conclusão: os resultados demonstraram interferência negativa da polimedicação na ocorrência de reações adversas, e nas potenciais interações medicamentosas totais e graves. Há necessidade de conhecer o impacto destas variáveis no paciente anticoagulado polimedicado para o planejamento de estratégias de redução de riscos e para a otimização dos benefícios.

Objectives: To evaluate the profile of the drugs for continuous use prescribed in Primary Health Care (PHC) in Santa Rosa / RS and to identify presence in the official lists of essential drugs. Methods: Cross-sectional, analytical and quantitative study, with analysis of the digital prescriptions of users of primary health care in Santa Rosa. There was no gender restriction and patients who used at least one chronic drug were included. Data were collected through a printed report from users. Results: The study included 642 participants, with a mean age of 60.40±14.48, 64.3% were female and 47.4%, using polypharmacy. A total of 3.009 drugs were identified, with an average of 4.69±2.82 medications/prescription. There was a higher frequency of the cardiovascular system (46.9%), nervous system (16.8%) and digestive tract and metabolism (14.8%). The most commonly used drugs were hydrochlorothiazide, fluoxetine and omeprazole. Regarding the presence of drugs in the official lists, 90.9% are in RENAME and 90.8% in REMUME, and 80% of users have obtained full access to medicines. In the prescriptions, 0.3% contained antibiotics, 1.3% injectable drugs and all drugs were prescribed by the generic name and in a computerized way. Conclusions: The pharmacotherapeutic profile is similar to the national reality and most indicators are as recommended by the WHO, demonstrating the organization of the PA of the city, which facilitates the access of users to essential medicines. However, there was a high number of drugs per prescription and presence of polypharmacy, evidencing the importance of access to it as well as the promotion of the rational use of these drugs.

Aim: To evaluate the impact of pharmacotherapeutic follow-up on bleeding, time in therapeutic range (TTR), thrombotic events, general adverse events, hospitalizations, drug interactions and average number of medications used in patients taking warfarin in the Brazilian public healthcare system. Methods: A randomized clinical trial was conducted with individuals divided into two groups (intervention group [pharmacotherapeutic follow-up] and control group) who received at-home visits over an eight-month period. Results: 38individuals (21 in the intervention group and 17 in the control group) concluded the study. Fewer number of cases of bleeding was found in the group that received pharmacotherapeutic follow-up, but no significant association was found between these variables. No significant association was found between pharmacotherapeutic follow-up and TTR. The intervention group had a greater frequency in the therapeutic range for capillary INR but not for laboratory INR. Reductions were found in the intervention group with regards to general adverse events, the use of medications and drug interactions, whereas no reduction was found in hospitalizations. Conclusions: Based on the findings of the present study, pharmacotherapeutic follow-up did not exert an influence on bleeding or TTR. However, reductions were found in adverse events and drug interactions, which can contribute to the rational use of medicines and could result in lower care costs for patients requiring blood thinners